FDA

Sales & Marketing

What can FDA really do about DTC pharma advertising?

What legal hurdles does the FDA face in changing the rules for broadcast advertising? And what should the industry be doing to prepare for changes?

News

Flood of warning letters follows DTC ad clampdown

The FDA has lost no time following through on its plan to tighten up DTC advertising of medicines, sending out dozens of untitled and warning letters.

News

FDA's Makary explains 'overdue' pharma ads crackdown

FDA Commissioner Marty Makary has called DTC ads for medicines a "public health crisis" as the industry prepares for a regulatory crackdown.

News

HHS, FDA drop major DTC advertising policy changes

HHS and FDA announced a new policy change that would require pharma companies to list drug information much more extensively in broadcast ads.

News

FDA lends a hand to Novo, Lilly on illegal GLP-1 imports

The FDA has set up a green list of overseas sources for GLP-1 ingredients to try to block imports of illegitimate and potentially unsafe materials.

News

FDA releases previously unseen CRLs in transparency push

The FDA's earlier decision to publish complete response letters was largely a repackaging of existing information, but now it has gone much further.

What can FDA really do about DTC pharma advertising?

Flood of warning letters follows DTC ad clampdown

FDA's Makary explains 'overdue' pharma ads crackdown

HHS, FDA drop major DTC advertising policy changes

FDA lends a hand to Novo, Lilly on illegal GLP-1 imports

FDA releases previously unseen CRLs in transparency push

Getting predictive technologies to patients, with Concr

Discover a new era of healthcare panel engagement: Grounded ...

FDA

Editor's Picks